New Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 371-379

Bentham Science Publishers

Access to resources Recommend Favorite

Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

By  

Current Cancer Drug Targets, Vol. 12, Iss. 4, 2012-04 ,pp. : 391-401

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By Alvarado Yesid   Kantarjian Hagop M.   Luthra Rajyalakshmi   Ravandi Farhad   Borthakur Gautam   Garcia-Manero Guillermo   Konopleva Marina   Estrov Zeev   Andreeff Michael   Cortes Jorge E.  

Cancer, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

Blackwell Publishing

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitor Resistance and Epigenetic Regulation of SHP1 Phosphatase Expression in Chronic Myeloid Leukemia

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 12, Iss. 4, 2014-12 ,pp. : 240-249

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

By Soverini Simona   Martinelli Giovanni   Rosti Gianantonio   Iacobucci Ilaria   Baccarani Michele  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1271-1284

Future Medicine

Access to resources Recommend Favorite